Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test

Analysts Skeptical About Taking On Established Players

 
• By Andrew McConaghie
  
The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine.
Moderna's long-term strategy is to combine its COVID=19, flu and RSV shots in one - but proving efficacy against competitors will be a challenge. • Source: JOSEPH PREZIOSO/AFP via Getty Images (JOSEPH PREZIOSO/AFP via Getty Images)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip